APL 40470/2024

—·EP3167888: TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT

Verfahrensdetails: Status
—
Verfahrensart
Berufung
Kategorie
Hauptberufung
Parteien: Kläger
Alexion Pharmaceuticals, Inc.
Vertreter: Wolrad Prinz zu Waldeck Und Pyrmont (Freshfields Bruckhaus Deringer); Christopher Stothers (Freshfields Bruckhaus Deringer); Elena Hennecke (Freshfields Bruckhaus Deringer); Gregor König (Szynka Tilmann von Renesse); Claudia Hertzsch (Szynka Tilmann von Renesse)
Beklagte
Samsung Bioepis NL B.V.
Vertreter: Andrea Ritter (Simmons & Simmons); Peter Meyer (Simmons & Simmons); Scott Parker (Simmons & Simmons); Elsa Glauert (Simmons & Simmons); Fritz Lahrtz (Simmons & Simmons)
Division: Court of Appeal
Richter: Klaus Grabinski · President of the Court of Appeal
Peter Blok · Legally qualified judge and judge-rapporteur
Emmanuel Gougé · Legally qualified judge
Eric Enderlin · Technically qualified judge
Anna Hedberg · Technically qualified judge
Technology: Organic Chemistry
Sprache: —
Erste Entscheidung: 20. Dez. 2024

Entscheidungen

2024-12-20
PI abgelehntBerufungsentscheidungAppeal RoP220.1
The Court of Appeal dismissed Alexion's appeal against the Hamburg Local Division's refusal to grant provisional measures against Samsung Bioepis regarding patent EP 3167888. The Court addressed the interpretation of patent claims containing linguistic errors and the relevance of prosecution history.
Rechtsfragen:Provisional measuresPatent claim interpretationLinguistic error in patent claimProsecution historyBiosimilar pharmaceutical

Dokumente